Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 26, Issue 12, Pages 1235-1250Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612826666200218101231
Keywords
Glaucoma; Alzheimer's disease; lipid nanoparticles; solid lipid nanoparticles; nanostructured lipid carriers; glaucoma
Categories
Funding
- Generalitat of Catalonia [2017SGR-1477]
- Portuguese Science and Technology Foundation (FCT/MCT)
- European Funds (PRODER/COMPETE) [M-ERA-NET/0004/2015PAIRED]
- FEDER, under the Partnership Agreement PT2020
Ask authors/readers for more resources
Glaucoma constitutes the second cause of blindness worldwide and it is considered a neurodegenerative disorder. In this sense, Alzheimer's disease, which is the most common type of dementia, also causes lieurodegeneration. The association between both diseases remains unknown although it has been hypothesised that a possible connection might exist and it will be analysed throughout the review. In this sense, nanoparticulate systems and specially, lipid nanoparticles could be the key for effective neuroprotection. Lipid nanoparticles are the most recent type of drug nanoparticulate systems. These nanoparticles have shown great potential to encapsulate hydrophobic drugs increasing their bioavailability and being able to deliver them to the target tissue. In addition, they have shown great potential for ocular drug delivery. This review explores the most recent strategies employing lipid nanoparticles for AD and glaucoma. c
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available